European Archives - Page 1120 of 1191 - European Medical Journal

EMJ

ARAMIS: Phase 3 trial of ODM-201 for high-risk non-metastatic castration-resistant prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Villejuif, France…

EMJ

Phase 1b trial of idelalisib in combination with chemoimmunotherapy for relapsed/refractory CLL

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the results of a phase 1b trial that…

EMJ

PALOMA-3: Palbociclib plus fulvestrant in hormone receptor-positive advanced breast cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill, NC…

EMJ

Immune responses and clinical outcomes in STAND trial of sipuleucel-T and ADT in prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses…

EMJ

ELOQUENT-2: Elotuzumab for relapsed/refractory multiple myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of…

EMJ

Phase 2 trial of brentuximab vedotin plus AVD for limited-stage Hodgkin lymphoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center…

EMJ

Towards precision medicine in cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, elected ASCO President for the 2015–2016 term, Julie M. Vose, MD, MBA, FASCO…

EMJ

Immunotherapy and targeted therapies in melanoma at ASCO 2015

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif, France, reviews…

EMJ

Focus on geriatric oncology at ASCO 2015

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Lodovico Balducci, MD, of Moffitt Cancer Center, Tampa, FL, explains the current…

EMJ

PFS and correlative biomarker analysis from the phase 3 coBRIM study

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale…